Float Short %

16.62

Margin Of Safety %

-26

Put/Call OI Ratio

0.85

EPS Next Q Diff

-0.36

EPS Last/This Y

EPS This/Next Y

-0.62

Price

30.03

Target Price

64.53

Analyst Recom

1.71

Performance Q

-3.64

Relative Volume

0.25

Beta

0.77

Ticker: IMCR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	IMCR	32.65	0.95	0.11	1567
2025-01-24	IMCR	33.05	0.94	0.00	1575
2025-01-27	IMCR	32.18	0.93	3.33	1584
2025-01-28	IMCR	32.08	0.93	0.03	1578
2025-01-29	IMCR	31.54	0.81	0.00	1693
2025-01-30	IMCR	32.64	0.81	0.00	1692
2025-01-31	IMCR	32.86	0.81	0.00	1692
2025-02-03	IMCR	31.22	0.81	0.00	1691
2025-02-04	IMCR	30.77	0.81	0.00	1692
2025-02-05	IMCR	30.7	0.81	25.00	1695
2025-02-06	IMCR	29.87	0.84	1.00	1720
2025-02-07	IMCR	30.22	0.84	0.00	1721
2025-02-10	IMCR	29.47	0.84	999.99	1721
2025-02-11	IMCR	28.21	0.84	0.00	1721
2025-02-12	IMCR	29.7	0.83	0.00	1731
2025-02-13	IMCR	29.87	0.83	0.00	1731
2025-02-14	IMCR	29.59	0.83	0.00	1731
2025-02-18	IMCR	29.08	0.84	0.08	1723
2025-02-19	IMCR	29.85	0.84	0.08	1723
2025-02-20	IMCR	29.96	0.83	4.33	1738
2025-02-21	IMCR	30.01	0.85	139.50	1767
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	IMCR	32.70	50.5	-81.7	-0.56
2025-01-24	IMCR	33.08	50.5	-74.9	-0.56
2025-01-27	IMCR	32.32	50.5	-69.9	-0.56
2025-01-28	IMCR	32.14	50.5	-72.5	-0.56
2025-01-29	IMCR	31.59	50.5	-70.7	-0.56
2025-01-30	IMCR	32.61	50.5	-77.9	-0.56
2025-01-31	IMCR	32.88	50.5	-74.4	-0.56
2025-02-03	IMCR	31.17	50.5	-65.1	-0.56
2025-02-04	IMCR	30.76	50.3	-71.0	-0.56
2025-02-05	IMCR	30.61	50.3	-72.0	-0.56
2025-02-06	IMCR	29.92	50.3	-69.6	-0.56
2025-02-07	IMCR	30.06	50.3	-73.5	-0.56
2025-02-10	IMCR	29.44	50.3	-69.8	-0.56
2025-02-11	IMCR	28.19	49.7	-66.2	-0.56
2025-02-12	IMCR	29.57	49.7	-81.0	-0.56
2025-02-13	IMCR	29.74	49.7	-74.0	-0.56
2025-02-14	IMCR	29.60	49.7	-72.3	-0.56
2025-02-18	IMCR	29.21	49.7	-70.9	-0.56
2025-02-19	IMCR	29.77	49.7	-76.2	-0.56
2025-02-20	IMCR	29.93	49.7	-73.9	-0.56
2025-02-21	IMCR	30.03	49.7	-73.9	-0.56
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	IMCR	0.00	22.17	13.82
2025-01-24	IMCR	0.00	22.17	13.82
2025-01-27	IMCR	0.00	22.77	13.82
2025-01-28	IMCR	0.00	22.77	13.79
2025-01-29	IMCR	0.00	22.77	13.79
2025-01-30	IMCR	0.00	22.77	13.79
2025-01-31	IMCR	0.00	22.77	13.79
2025-02-03	IMCR	0.00	23.42	13.79
2025-02-04	IMCR	0.00	23.42	13.79
2025-02-05	IMCR	0.00	23.42	13.79
2025-02-06	IMCR	0.00	23.42	13.79
2025-02-07	IMCR	0.00	23.42	13.79
2025-02-10	IMCR	0.00	22.36	13.79
2025-02-11	IMCR	0.00	22.36	13.79
2025-02-12	IMCR	0.00	22.36	15.08
2025-02-13	IMCR	0.00	22.36	15.08
2025-02-14	IMCR	0.00	22.36	15.08
2025-02-18	IMCR	0.00	19.42	15.08
2025-02-19	IMCR	0.00	19.42	15.08
2025-02-20	IMCR	0.00	19.42	15.08
2025-02-21	IMCR	0.00	19.42	16.62
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.17

Avg. EPS Est. Current Quarter

-0.16

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

Institutional Transactions

19.42

Beta

0.77

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

22.16

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

64.53

P/E

Forward P/E

PEG

P/S

5.03

P/B

3.98

P/Free Cash Flow

71.42

EPS

-0.96

Average EPS Est. Cur. Y

-0.56

EPS Next Y. (Est.)

-1.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-15.83

Relative Volume

0.25

Return on Equity vs Sector %

-31.7

Return on Equity vs Industry %

-16.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

-73.9

Immunocore Holdings plc

Sector: Healthcare

Industry: Biotechnology

Employees: 497

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today

news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance

stock history IMCR – Immunocore Holdings plc ADR invest stock market

stock prices IMCR premarket after hours

ticker IMCR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IMCR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y